Risk factors for Barrett's esophagus

Journal of Digestive Diseases

Volumn 17, Issue 4, 2016, Pages 215-221

  Arora, Zubin ^a   Garber, Ari ^a   Thota, Prashanthi N ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Barrett esophagus; gastroesophageal reflux; risk factors

Indexed keywords

ALCOHOL; BISPHOSPHONIC ACID DERIVATIVE;

ABDOMINAL OBESITY; AGE; ALCOHOL CONSUMPTION; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; DIABETES MELLITUS; FAMILY HISTORY; GASTROESOPHAGEAL REFLUX; HUMAN; LOW BIRTH WEIGHT; METABOLIC SYNDROME X; PRIORITY JOURNAL; RACE; RISK FACTOR; SEX; SLEEP DISORDERED BREATHING; SMOKING; WAIST HIP RATIO;

EID: 84979239914     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12332     Document Type: Article

References (78)

1. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol 2016; 111: 30–50.
2. di Pietro M, Alzoubaidi D, Fitzgerald RC. Barrett's esophagus and cancer risk: how research advances can impact clinical practice. Gut Liver 2014; 8: 356–70.
3. Corley DA, Kubo A, Levin TR et al. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994–2006. Gut 2009; 58: 182–8.
4. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005; 54: 1062–6.
5. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142–6.
6. Shiota S, Singh S, Anshasi A, El-Serag HB. Prevalence of Barrett's esophagus in Asian countries: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13: 1907–18.
7. Rubenstein JH. Risk factors for Barrett's esophagus. Curr Opin Gastroenterol 2014; 30: 408–14.
8. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 1975; 70: 826–35.
9. Anderson LA, Watson RG, Murphy SJ et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 2007; 13: 1585–94.
10. Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. Am J Gastroenterol 2010; 105: 1729, 1730–7; quiz 1738.
11. Fass R, Hell RW, Garewal HS et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 2001; 48: 310–3.
12. Wang DH, Clemons NJ, Miyashita T et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology 2010; 138: 1810–22.
13. Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med 2014; 371: 836–45.
14. Singh P, Taylor RH, Colin-Jones DG. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present. Am J Gastroenterol 1994; 89: 349–56.
15. Neumann CS, Cooper BT. 24 hour ambulatory oesophageal pH monitoring in uncomplicated Barrett's oesophagus. Gut 1994; 35: 1352–5.
16. Thrift AP, Kramer JR, Qureshi Z, Richardson PA, El-Serag HB. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol 2013; 108: 915–22.
17. Dvorak K, Payne CM, Chavarria M et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 2007; 56: 763–71.
18. McQuaid KR, Laine L, Fennerty MB, Souza R, Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther 2011; 34: 146–65.
19. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 1999; 94: 2054–9.
20. Buttar NS, Falk GW. Pathogenesis of gastroesophageal reflux and Barrett esophagus. Mayo Clin Proc 2001; 76: 226–34.
21. Gordon C, Kang JY, Neild PJ, Maxwell JD. The role of the hiatus hernia in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20: 719–32.
22. Andrici J, Tio M, Cox MR, Eslick GD. Hiatal hernia and the risk of Barrett's esophagus. J Gastroenterol Hepatol 2013; 28: 415–31.
23. Ronkainen J, Talley NJ, Storskrubb T et al. Erosive esophagitis is a risk factor for Barrett's esophagus: a community-based endoscopic follow-up study. Am J Gastroenterol 2011; 106: 1946–52.
24. Bai Y, Du Y, Zou D et al.; Chinese GerdQ Research Group. Gastroesophageal Reflux Disease Questionnaire (GerdQ) in real-world practice: a national multicenter survey on 8065 patients. J Gastroenterol Hepatol 2013; 28: 626–31.
25. Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 2005; 162: 454–60.
26. Wang A, Mattek NC, Holub JL, Lieberman DA, Eisen GM. Prevalence of complicated gastroesophageal reflux disease and Barrett's esophagus among racial groups in a multi-center consortium. Dig Dis Sci 2009; 54: 964–71.
27. Falk GW, Thota PN, Richter JE, Connor JT, Wachsberger DM. Barrett's esophagus in women: demographic features and progression to high-grade dysplasia and cancer. Clin Gastroenterol Hepatol 2005; 3: 1089–94.
28. van Blankenstein M, Looman CW, Johnston BJ, Caygill CP. Age and sex distribution of the prevalence of Barrett's esophagus found in a primary referral endoscopy center. Am J Gastroenterol 2005; 100: 568–76.
29. Masclee GM, Coloma PM, de Wilde M, Kuipers EJ, Sturkenboom MC. The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off. Aliment Pharmacol Ther 2014; 39: 1321–30.
30. Watari J, Hori K, Toyoshima F et al. Association between obesity and Barrett's esophagus in a Japanese population: a hospital-based, cross-sectional study. BMC Gastroenterol 2013; 13: 143.
31. Adeniyi KO. Gastric acid secretion and parietal cell mass: effect of sex hormones. Gastroenterology 1991; 101: 66–9.
32. Namiot Z, Sarosiek J, Rourk RM, Hetzel DP, McCallum RW. Human esophageal secretion: mucosal response to luminal acid and pepsin. Gastroenterology 1994; 106: 973–81.
33. Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol 2001; 33: 306–9.
34. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago (GOSPE). Barrett's esophagus: epidemiological and clinical results of a multicentric survey. Int J Cancer 1991; 48: 364–8.
35. Butorin NN, Bichurina TB, Tsukanov VV et al. The prevalence and clinical aspects of Barrett's esophagus in the population of eastern Siberia. Ter Arkh 2013; 85: 62–5 (in Russian).
36. Kim JH, Rhee PL, Lee JH et al. Prevalence and risk factors of Barrett's esophagus in Korea. J Gastroenterol Hepatol 2007; 22: 908–12.
37. Xiong LS, Cui Y, Wang JP et al. Prevalence and risk factors of Barrett's esophagus in patients undergoing endoscopy for upper gastrointestinal symptoms. J Dig Dis 2010; 11: 83–7.
38. Chak A. Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 2006; 15: 1668–73.
39. Chak A, Lee T, Kinnard MF et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002; 51: 323–8.
40. Verbeek RE, Spittuler LF, Peute A et al. Familial clustering of Barrett's esophagus and esophageal adenocarcinoma in a European cohort. Clin Gastroenterol Hepatol 2014; 12: 1656–63.e1.
41. Chak A, Faulx A, Kinnard M et al. Identification of Barrett's esophagus in relatives by endoscopic screening. Am J Gastroenterol 2004; 99: 2107–14.
42. Levine DM, Ek WE, Zhang R et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet 2013; 45: 1487–93.
43. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199–211.
44. Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 2619–28.
45. Crowell MD, Bradley A, Hansel S et al. Obesity is associated with increased 48-h esophageal acid exposure in patients with symptomatic gastroesophageal reflux. Am J Gastroenterol 2009; 104: 553–9.
46. Nadaleto BF, Herbella FA, Patti MG. Gastroesophageal reflux disease in the obese: Pathophysiology and treatment. Surgery 2016; 159: 475–86.
47. Bu X, Ma Y, Der R, Demeester T, Bernstein L, Chandrasoma PT. Body mass index is associated with Barrett esophagus and cardiac mucosal metaplasia. Dig Dis Sci 2006; 51: 1589–94.
48. Stein DJ, El-Serag HB, Kuczynski J, Kramer JR, Sampliner RE. The association of body mass index with Barrett's oesophagus. Aliment Pharmacol Ther 2005; 22: 1005–10.
49. Cook MB, Greenwood DC, Hardie LJ, Wild CP, Forman D. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 2008; 103: 292–300.
50. Nelsen EM, Kirihara Y, Takahashi N et al. Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2012; 10: 728–34; quiz e61-2.
51. Kubo A, Cook MB, Shaheen NJ et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut 2013; 62: 1684–91.
52. Singh S, Sharma AN, Murad MH et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1399–412.e7.
53. El-Serag HB, Hashmi A, Garcia J et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut 2014; 63: 220–9.
54. Alexandre L, Long E, Beales IL. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol 2014; 5: 534–49.
55. Rubenstein JH, Morgenstern H, Chey WD et al. Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. Gut 2014; 63: 230–5.
56. Cook MB, Shaheen NJ, Anderson LA et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 2012; 142: 744–53.
57. Andrici J, Cox MR, Eslick GD. Cigarette smoking and the risk of Barrett's esophagus: a systematic review and meta-analysis. J Gastroenterol Hepatol 2013; 28: 1258–73.
58. Steevens J, Schouten LJ, Driessen AL et al. A prospective cohort study on overweight, smoking, alcohol consumption, and risk of Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2011; 20: 345–58.
59. Thrift AP, Kramer JR, Richardson PA, El-Serag HB. No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus. Dig Dis Sci 2014; 59: 108–16.
60. Yates M, Cheong E, Luben R et al. Body mass index, smoking, and alcohol and risks of Barrett's esophagus and esophageal adenocarcinoma: a UK prospective cohort study. Dig Dis Sci 2014; 59: 1552–9.
61. Thrift AP, Cook MB, Vaughan TL et al. Alcohol and the risk of Barrett's esophagus: a pooled analysis from the International BEACON Consortium. Am J Gastroenterol 2014; 109: 1586–94.
62. Xu Q, Guo W, Shi X et al. Association between alcohol consumption and the risk of Barrett's esophagus: a meta-analysis of observational studies. Medicine (Baltimore) 2015; 94: e1244.
63. Iyer PG, Borah BJ, Heien HC, Das A, Cooper GS, Chak A. Association of Barrett's esophagus with type II diabetes mellitus: results from a large population-based case-control study. Clin Gastroenterol Hepatol 2013; 11: 1108–14.e5.
64. Chen SC, Chou CK, Wong FH, Chang CM, Hu CP. Overexpression of epidermal growth factor and insulin-like growth factor-I receptors and autocrine stimulation in human esophageal carcinoma cells. Cancer Res 1991; 51: 1898–903.
65. Liu YC, Leu CM, Wong FH et al. Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci 2002; 9: 665–74.
66. Takaoka M, Harada H, Andl CD et al. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res 2004; 64: 7711–23.
67. Leggett CL, Gorospe EC, Calvin AD et al. Obstructive sleep apnea is a risk factor for Barrett's esophagus. Clin Gastroenterol Hepatol 2014; 12: 583–8.e1.
68. Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest 2010; 137: 711–9.
69. Kerr P, Shoenut JP, Millar T, Buckle P, Kryger MH. Nasal CPAP reduces gastroesophageal reflux in obstructive sleep apnea syndrome. Chest 1992; 101: 1539–44.
70. Friedman M, Gurpinar B, Lin HC, Schalch P, Joseph NJ. Impact of treatment of gastroesophageal reflux on obstructive sleep apnea-hypopnea syndrome. Ann Otol Rhinol Laryngol 2007; 116: 805–11.
71. Tawk M, Goodrich S, Kinasewitz G, Orr W. The effect of 1 week of continuous positive airway pressure treatment in obstructive sleep apnea patients with concomitant gastroesophageal reflux. Chest 2006; 130: 1003–8.
72. Leggett CL, Nelsen EM, Tian J et al. Metabolic syndrome as a risk factor for Barrett esophagus: a population-based case-control study. Mayo Clin Proc 2013; 88: 157–65.
73. Forssell L, Cnattingius S, Bottai M et al. Increased risk of Barrett's esophagus among individuals born preterm or small for gestational age. Clin Gastroenterol Hepatol 2013; 11: 790–4.
74. Kaijser M, Akre O, Cnattingius S, Ekbom A. Preterm birth, low birth weight, and risk for esophageal adenocarcinoma. Gastroenterology 2005; 128: 607–9.
75. Lin D, Kramer JR, Ramsey D et al. Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. Am J Gastroenterol 2013; 108: 1576–83.
76. Liu X, Wong A, Kadri SR et al. Gastro-esophageal reflux disease symptoms and demographic factors as a pre-screening tool for Barrett's esophagus. PLoS One 2014; 9: e94163.
77. Thrift AP, Kendall BJ, Pandeya N et al. A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila) 2012; 5: 1115–23.
78. Rubenstein JH, Morgenstern H, Appelman H et al. Prediction of Barrett's esophagus among men. Am J Gastroenterol 2013; 108: 353–62.